Buprenorphine — Discount Pricing

Other medications in Pain & Inflammation

• Butorphanol
• Caffeine-Ergotamine
• Capsaicin
• Capsaicin Patch
• Carisoprodol
• Chlorzoxazone
• Codeine
• Dantrolene

What Buprenorphine is approved for (FDA label)

SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. SUBLOCADE contains buprenorphine, a partial opioid agonist, and is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. ( 1 ) SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 27, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Buprenorphine (FDA label)

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously. ( 5.1 ) Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. ( 5.2 ) WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY See full prescribing information for complete boxed warning. Serious harm or death could result if administered intravenously. ( 5.1 ) SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. ( 5.2 )

Source: FDA prescribing information (DailyMed). Set ID: 6189fb21-9432-45f8-8481-0bfaf3ccde95. SPL document ID: 5799c0fd-6d82-f48a-e063-6394a90a63d6. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Buprenorphine (FDA label)

SUBLOCADE injection is available in dosage strengths of 100 mg/0.5 mL and 300 mg/1.5 mL buprenorphine. Each injection is a sterile, clear, colorless to yellow to amber solution provided in a single-dose, prefilled syringe with a 19 gauge 5/8-inch needle. Injection: 100 mg/0.5 mL and 300 mg/1.5 mL provided in a prefilled, single-dose syringe with a 19 Gauge 5/8-inch needle. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 6189fb21-9432-45f8-8481-0bfaf3ccde95. SPL document ID: 5799c0fd-6d82-f48a-e063-6394a90a63d6. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Buprenorphine (FDA label)

The following adverse reactions are discussed in more detail in other sections of the labeling: Addiction, Abuse, and Misuse [see Warnings and Precautions ( 5.3 )] Respiratory and CNS Depression [see Warnings and Precautions ( 5.4 )] Neonatal Opioid Withdrawal Syndrome [see Warnings and Precautions ( 5.7 )] Adrenal Insufficiency [see Warnings and Precautions ( 5.8 )] Opioid Withdrawal [see Warnings and Precautions ( 5.9 , 5.12 )] Hepatitis, Hepatic Events [see Warnings and Precautions ( 5.10 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.11 )] Orthostatic Hypotension [see Warnings and Precautions ( 5.18 )] Elevation of Cerebrospinal Fluid Pressure [see Warnings and Precautions ( 5.19 )] Elevation of Intracholedochal Pressure [see Warnings and Precautions ( 5.20 )] Adverse reactions commonly associated with SUBLOCADE (in ≥ 5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Indivior Inc. at 1-877-782-6966 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 6189fb21-9432-45f8-8481-0bfaf3ccde95. SPL document ID: 5799c0fd-6d82-f48a-e063-6394a90a63d6. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Buprenorphine (FDA label)

SUBLOCADE should not be administered to patients who have been shown to be hypersensitive to buprenorphine or any component of the ATRIGEL ® delivery system [see Warnings and Precautions ( 5.11 )] . Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 6189fb21-9432-45f8-8481-0bfaf3ccde95. SPL document ID: 5799c0fd-6d82-f48a-e063-6394a90a63d6. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Buprenorphine (FDA label)

Addiction, Abuse, and Misuse : Buprenorphine can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. ( 5.3 ) Respiratory Depression : Life-threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. ( 5.4 , 5.5 ) Risk of Serious Injection Site Reactions : Likelihood may be increased with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. ( 5.6 ).

Source: FDA prescribing information (DailyMed). Set ID: 6189fb21-9432-45f8-8481-0bfaf3ccde95. SPL document ID: 5799c0fd-6d82-f48a-e063-6394a90a63d6. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Buprenorphine (FDA label)

Table 5 includes clinically significant drug interactions with SUBLOCADE. Table 5 Clinically Significant Drug Interactions Benzodiazepines and Other Central Nervous System (CNS) Depressants Clinical Impact: Due to additive pharmacologic effects, the concomitant use of benzodiazepines or other CNS depressants, including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death. Intervention: Cessation of benzodiazepines or other CNS depressants is preferred in most cases of concomitant use. In some cases, monitoring in a higher level of care for taper may be appropriate. In others, gradually tapering a patient off of a prescribed benzodiazepine or other CNS depressant or decreasing to the lowest effective dose may be appropriate. Similarly, cessation of other CNS depressants is preferred when possible.

Source: FDA prescribing information (DailyMed). Set ID: 6189fb21-9432-45f8-8481-0bfaf3ccde95. SPL document ID: 5799c0fd-6d82-f48a-e063-6394a90a63d6. Label effective date: July 27, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.